{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:37:54Z","timestamp":1793144274658,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejim.2023.06.012","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T02:03:34Z","timestamp":1686881014000},"page":"104-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Phenotypic Profiles Among 72 Caucasian and Afro-Caribbean Patients with Antisynthetase Syndrome Involving Anti-PL7 or Anti-PL12 Autoantibodies"],"prefix":"10.1016","volume":"115","author":[{"given":"Aurore","family":"Abel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estibaliz","family":"Lazaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamy","family":"Ralazamahaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Pierrisnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Suzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1493-7390","authenticated-orcid":false,"given":"Patrick","family":"Merci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Macey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4922-5222","authenticated-orcid":false,"given":"Moustapha","family":"Agossou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Deligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0254-3394","authenticated-orcid":false,"given":"Etienne","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2023.06.012_bib0001","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.06.012_bib0002","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J. Bras. Pneumol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.ejim.2023.06.012_bib0004","doi-asserted-by":"crossref","first-page":"309","DOI":"10.55563\/clinexprheumatol\/8xj0b9","article-title":"Defining anti-synthetase syndrome: a systematic literature review","volume":"40","author":"Zanframundo","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0005","unstructured":"EULAR | Recommendations and initiatives EULAR\/acr. https:\/\/www.eular.org\/recommendations_eular_acr.cfm."},{"key":"10.1016\/j.ejim.2023.06.012_bib0006","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-015-0532-1","article-title":"Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome","volume":"17","author":"Ascherman","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.ejim.2023.06.012_bib0007","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.tibs.2022.09.011","article-title":"Mechanistic perspectives on anti-aminoacyl-tRNA synthetase syndrome","volume":"48","author":"Kanaji","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejim.2023.06.012_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866087","article-title":"Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond","volume":"13","author":"Galindo-Feria","year":"2022","journal-title":"Front. Immunol"},{"key":"10.1016\/j.ejim.2023.06.012_bib0009","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/art.1780230802","article-title":"Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis","volume":"23","author":"Nishikai","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.06.012_bib0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1084\/jem.160.2.420","article-title":"Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody","volume":"160","author":"Mathews","year":"1984","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0011","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.163.5.1281","article-title":"Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis","volume":"163","author":"Bunn","year":"1986","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0012","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/art.1780350718","article-title":"Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease","volume":"35","author":"Targoff","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.06.012_bib0013","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1172\/JCI116493","article-title":"Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase","volume":"91","author":"Targoff","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejim.2023.06.012_bib0014","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4049\/jimmunol.162.4.2315","article-title":"Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease","volume":"162","author":"Hirakata","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0015","first-page":"S312","article-title":"Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome (abstract)","volume":"52","author":"Hashish","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.06.012_bib0016","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kem045","article-title":"Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia","volume":"46","author":"Betteridge","year":"2007","journal-title":"Rheumatol"},{"key":"10.1016\/j.ejim.2023.06.012_bib0017","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11926-013-0349-8","article-title":"Clinical heterogeneity and outcomes of antisynthetase syndrome","volume":"15","author":"Hervier","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.ejim.2023.06.012_bib0018","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0019","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejim.2023.06.012_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rmed.2016.12.014","article-title":"Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS\/ERS criteria for interstitial pneumonia with autoimmune features (IPAF)","volume":"123","author":"Mej\u00eda","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0021","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3899\/jrheum.181141","article-title":"Evolution of Pulmonary Function in a Cohort of Patients with Interstitial Lung Disease and Positive for Antisynthetase Antibodies","volume":"47","author":"Gonz\u00e1lez-P\u00e9rez","year":"2020","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12890-021-01399-5","article-title":"Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China","volume":"21","author":"Zhan","year":"2021","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0023","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejim.2023.06.012_bib0024","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study","author":"Bozzalla-Cassione","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0025","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/kes167","article-title":"Idiopathic inflammatory myositis-associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort","volume":"51","author":"Chua","year":"2012","journal-title":"Rheumatol"},{"key":"10.1016\/j.ejim.2023.06.012_bib0026","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatol"},{"key":"10.1016\/j.ejim.2023.06.012_bib0027","doi-asserted-by":"crossref","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and Dermatomyositis. doi:10.1056\/NEJM197502132920706.","DOI":"10.1056\/NEJM197502132920706"},{"key":"10.1016\/j.ejim.2023.06.012_bib0028","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An Official American Thoracic Society\/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0029","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/brain\/awq270","volume":"133","year":"2010","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejim.2023.06.012_bib0031","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: Initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0032","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal Muscle Involvement in Antisynthetase Syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejim.2023.06.012_bib0033","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-017-1219-y","article-title":"Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: a cross-sectional study","volume":"19","author":"Andersson","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejim.2023.06.012_bib0034","doi-asserted-by":"crossref","first-page":"A266","DOI":"10.1016\/j.revmed.2021.10.205","article-title":"Performances de l'IRM musculaire pour le diagnostic des myopathies auto-immunes : \u00e9tude prospective multicentrique (DARWIM)","volume":"42","author":"Allenbach","year":"2021","journal-title":"Rev. M\u00e9decine Interne"},{"key":"10.1016\/j.ejim.2023.06.012_bib0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","article-title":"Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome","volume":"24","author":"Marie","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0036","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1183\/09031936.00104310","article-title":"Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies","volume":"37","author":"Hervier","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejim.2023.06.012_bib0037","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/kep455","article-title":"Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases","volume":"49","author":"Hervier","year":"2010","journal-title":"Rheumatol"},{"key":"10.1016\/j.ejim.2023.06.012_bib0038","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1378\/chest.08-2233","article-title":"Clinical Profile of Anti-PL-12 Autoantibody","volume":"135","author":"Kalluri","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.06.012_bib0039","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MD.0b013e318260977c","article-title":"Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature","volume":"91","author":"Labirua-Iturburu","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejim.2023.06.012_bib0040","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejim.2023.06.012_bib0041","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00415-014-7623-1","article-title":"Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography","volume":"262","author":"Rosenbohm","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0042","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejim.2023.06.012_bib0043","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10067-021-05879-1","article-title":"Myositis autoantibodies in Iranian myositis patients: assessment the frequency and clinical relevancy","volume":"41","author":"Ebrahimi","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0044","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatol"},{"key":"10.1016\/j.ejim.2023.06.012_bib0046","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/14397595.2015.1091155","article-title":"Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52","volume":"26","author":"Yamasaki","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0068","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1468-1331.2010.03012.x","article-title":"EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia","volume":"17","author":"Kyriakides","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0069","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome \u2013 much more than just a myopathy","volume":"51","author":"Opinc","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejim.2023.06.012_bib0045","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.revmed.2013.12.006","article-title":"Auto-anticorps au cours des myosites","volume":"35","author":"Allenbach","year":"2014","journal-title":"Rev. M\u00e9decine Interne"},{"key":"10.1016\/j.ejim.2023.06.012_bib0047","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/medicina57040347","article-title":"Management of Myositis-Associated Interstitial Lung Disease","volume":"57","author":"Fujisawa","year":"2021","journal-title":"Medicina (Mex.)"},{"key":"10.1016\/j.ejim.2023.06.012_bib0048","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy","volume":"94","author":"Joffe","year":"1993","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0049","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0050","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3899\/jrheum.161217","article-title":"Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort","volume":"44","author":"Sharma","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0051","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.06.012_bib0052","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","article-title":"Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0053","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol. Hoboken NJ"},{"key":"10.1016\/j.ejim.2023.06.012_bib0054","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatol"},{"key":"10.1016\/j.ejim.2023.06.012_bib0055","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","article-title":"Tacrolimus in refractory polymyositis with interstitial lung disease","volume":"353","author":"Oddis","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.06.012_bib0056","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3899\/jrheum.180778","article-title":"Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis\/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis","volume":"46","author":"Hozumi","year":"2019","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0057","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: A randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirol. Carlton Vic"},{"key":"10.1016\/j.ejim.2023.06.012_bib0058","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3899\/jrheum.111604","article-title":"Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use","volume":"39","author":"Stanciu","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0059","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejim.2023.06.012_bib0060","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211060907","article-title":"Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease","volume":"13","author":"Wilfong","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.ejim.2023.06.012_bib0061","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.revmed.2013.09.003","article-title":"[Clinical phenotypes and prognosis of antisynthetase syndrome]","volume":"35","author":"Hervier","year":"2014","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.ejim.2023.06.012_bib0062","first-page":"1","article-title":"Clinical experience in anti-synthetase syndrome: a monocentric retrospective analytical study","author":"Maloir","year":"2021","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.ejim.2023.06.012_bib0063","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020","volume":"51","author":"Sun","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejim.2023.06.012_bib0064","doi-asserted-by":"crossref","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejim.2023.06.012_bib0065","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0066","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672008","article-title":"Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review","volume":"12","author":"Aguilar-Vazquez","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejim.2023.06.012_bib0067","series-title":"Ethnic groups worldwide: a ready reference handbook","author":"Levinson","year":"1998"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523002066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523002066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:40:11Z","timestamp":1760607611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523002066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":69,"alternative-id":["S0953620523002066"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.06.012","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotypic Profiles Among 72 Caucasian and Afro-Caribbean Patients with Antisynthetase Syndrome Involving Anti-PL7 or Anti-PL12 Autoantibodies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}